Fig. 5: Neoadjuvant ICI-induced TCR repertoire and immune cell changes.
From: Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
a, TCRβ and TCRγ clone numbers, Shannon diversity index and Shannon equitability index scores (measurement of the similarity of clone sizes) increased after neoadjuvant ICIs in the tumor (pretreatment (day −4) and posttreatment (day +13)) and blood specimens (pretreatment (day −9) and posttreatment (days +7 and +12)). b, The TCR clone size (clonotype total reads expressed as a percentage of total productive reads) of the 25 largest TCR clonotypes in each sample. The largest clones are at the bottom of each column. c, Upset plot of the shared TCRβ clonotypes across tumor (before and after) and blood specimens (day −9, day +7, day +12). The vertical bars indicate the number of clonotypes; the sample distribution patterns are indicated below the chart and are represented by filled points linked by the lines. A filled circle indicates that clones were detected in the corresponding samples; a gray circle indicates that TCR clones were not detected. The first five vertical bars show clonotypes unique to each of the specimens. The horizontal bars (lower left) show the number of TCRβ clones in each sample. d, Tracking the origin of clonotypes detected in the posttreatment tumor specimen. TCRβ clonotypes were classified based on whether they were unique to the posttreatment sample (63.65% of clonotypes) or shared with any of the PBMC samples (blood), the pretreatment tumor sample or both the pretreatment tumor and blood. The number in the center indicates the number of productive TCRβ clonotypes in the posttreatment tumor sample. e, Details of the size (clonotype total reads/sample total reads expressed as a percentage) of TCRβ clonotypes identified in the posttreatment tumor according to their origin (that is, identified in PBMC sample (blood), the pretreatment tumor sample or both the pretreatment tumor and blood samples). Most expanded clones (accounting for more than 1% of the sample total reads) were shared with the pretreatment tumor and blood samples.
